Abstract from Interim Report Q4-2009

ABSTRACT FROM INTERIM REPORT Q4-2009 / FULL YEAR BULLETIN 2009

Read the full Abstract


FOURTH QUARTER

• Net sales SKr 44.1 (35.0) million – increased with 26 %
• EBITDA SKr 9.3 (5.9) million – increased with SKr 3.3 million
• Earnings before tax SKr 7.4 (4.3) million
• Net earnings SKr 8.5 (3.3) million
• Earnings per share SKr 0.42 (0.16)

FULL YEAR / YEAR-TO-DATE
• Net sales SKr 136.7 (109.0) million – increased with 25 %
• EBITDA SKr 16.9 (3.4) million –increased with SKr 13.5 million
• Earnings before tax SKr 11.4 (5.2) million
• Net earnings SKr 33.5 (20.2) million*
• Earnings per share SKr 1.67 (1.01)
(* including deferred income tax of SKr 22.0 (16.0) million

BUSINESS PROGRESS
• Year ended strongly with a growth in sales of 26 % in Q4
• EBITDA margin 21 % in Q4
• Good sales development in USA
• Continuing sales growth for Osstell and Q-Sense
• Preferential rights issue fully subscribed
• Good outlooks for 2010

CEO COMMENT
“Net sales increased with 26 % in Q4, which was the seventeenth consecutive quarter with sales growth. A continuing strong gross margin of 77 % and limited cost increases led to an EBITDA margin of 21 % in the quarter. For the full year, we achieved a growth in sales of 25 % and an EBITDA margin of 12 %, which exceeded our 2009 targets. During 2009, we made several important product introductions, including the new Osstell ISQ and the new product brand Attension. We also strengthened our sales organisation with a new sales office in the UK and a liaison office in China and the establishment of a sales organisation for Osstell in the USA. The rights issue at the end of the year provides the financing for our continued organic expansion and allows us to make complementary acquisitions. All together, this means that we continue to work with ambitious targets for sales growth and profitability for 2010,” says Fredrik Lindgren, CEO of Biolin Scientific.